Shapeshifting microrobots can brush and floss teeth

A shapeshifting robotic microswarm may one day act as a toothbrush, rinse, and dental floss in one. The technology, developed by a multidisciplinary team at the University of Pennsylvania, is poised to offer a new and automated way to perform the mundane but critical daily tasks of brushing and flossing. It’s a system that could be particularly valuable for those who lack the manual dexterity to clean their teeth effectively themselves.
The building blocks of these microrobots are iron oxide nanoparticles that have both catalytic and magnetic activity. Using a magnetic field, researchers could direct their motion and configuration to form either bristle-like structures that sweep away dental plaque from the broad surfaces of teeth, or elongated strings that can slip between teeth like a length of floss. In both instances, a catalytic reaction drives the nanoparticles to produce antimicrobials that kill harmful oral bacteria on site.
Experiments using this system on mock and real human teeth showed that the robotic assemblies can conform to a variety of shapes to nearly eliminate the sticky biofilms that lead to cavities and gum disease. The Penn team shared their findings establishing a proof-of-concept for the robotic system in the journal ACS Nano.
“Routine oral care is cumbersome and can pose challenges for many people, especially those who have hard time cleaning their teeth” says Hyun (Michel) Koo, a professor in the Department of Orthodontics and divisions of Community Oral Health and Pediatric Dentistry in Penn’s School of Dental Medicine and co-corresponding author on the study. “You have to brush your teeth, then floss your teeth, then rinse your mouth; it’s a manual, multi-step process. The big innovation here is that the robotics system can do all three in a single, hands-free, automated way.”
“Nanoparticles can be shaped and controlled with magnetic fields in surprising ways,” says Edward Steager, a senior research investigator in Penn’s School of Engineering and Applied Science and co-corresponding author. “We form bristles that can extend, sweep, and even transfer back and forth across a space, much like flossing. The way it works is similar to how a robotic arm might reach out and clean a surface. The system can be programmed to do the nanoparticle assembly and motion control automatically.”
Disrupting oral care technology
“The design of the toothbrush has remained relatively unchanged for millennia,” says Koo.

Read more →

New research challenges long-held beliefs about limb regeneration

Ken Muneoka is no stranger to disrupting the field of regeneration; for example, in a 2019 ground-breaking publication in Nature, the Texas A&M University College of Veterinary Medicine & Biomedical Sciences (CVMBS) professor proved for the first time that joint regeneration in mammals was possible.
Now, his team is again challenging other centuries-old beliefs about the fundamental science of the field, this time related to how mammals might regenerate damaged parts of the body.
In humans, the natural ability to regenerate is limited to tissues like the epidermis, the outermost layer of skin, and some organs, such as the liver.
Other species, most notably salamanders, have the ability to regenerate complex structures such as bones, joints, and even entire limbs. As a result, scientists have been studying these species for more than 200 years to try to understand the mechanisms behind limb regeneration in the hopes of someday translating those mechanisms to induce more extensive regeneration in humans.
That research has led to a common belief that the single biggest key for limb regeneration is the presence of nerves.
While that may be true for salamanders and other species, it isn’t the case in mammals, according to two of Muneoka’s recently published studies. The first study, published last year in the Journal of Bone and Mineral Research, established that mechanical loading (the ability to apply force to or with an affected area) is a requirement for mammals. The second, published earlier this year in Developmental Biology, established that the absence of nerves does not inhibit regeneration.

Read more →

Inhalable COVID-19 vaccine shows promise in rodent model

Researchers have created an inhalable COVID-19 vaccine that is shelf stable at room temperature for up to three months, targets the lungs specifically and effectively, and allows for self-administration via an inhaler. The researchers also found that the delivery mechanism for this vaccine — a lung-derived exosome called LSC-Exo — is more effective at evading the lung’s mucosal lining than the lipid-based nanoparticles currently in use, and can be used effectively with protein-based vaccines.
Ke Cheng, the Randall B. Terry Jr. Distinguished Professor in Regenerative Medicine at NC State and a professor in the NC State/UNC-Chapel Hill Joint Department of Biomedical Engineering, along with colleagues from UNC-Chapel Hill and Duke University, led the development of the vaccine prototype from proof-of-concept to animal studies.
“There are several challenges associated with vaccine delivery we wanted to address,” Cheng says. “First, taking the vaccine via intramuscular shot is less efficient at getting it into the pulmonary system, and so can limit its efficacy. Inhaled vaccines would increase their benefit against COVID-19.
“Second, mRNA vaccines in their current formulation require cold storage and trained medical personnel to deliver them. A vaccine that is stable at room temperature and that could be self-administered would greatly reduce wait times for patients as well as stress on the medical profession during a pandemic. However, reformulating the delivery mechanism is necessary for it to work through inhalation.”
In order to deliver the vaccine directly to the lungs, the researchers used exosomes (Exo) secreted from lung spheroid cells (LSCs). Exosomes are nanosized vesicles that have recently been recognized as an excellent means of drug delivery.
First, the researchers looked at whether LSC-Exo was able to deliver protein or mRNA “cargos” throughout the lungs. The researchers compared the distribution and retention of LSC-Exo to nanoparticles similar to lipid nanoparticles currently used with mRNA vaccines. In a paper in Extracellular Vesicle, the researchers demonstrated that lung-derived nanoparticles were more effective at delivering mRNA and protein cargo to bronchioles and deep lung tissue than synthetic liposome particles.
Next, the researchers created and tested an inhalable, protein-based, virus-like particle (VLP) vaccine by decorating the exterior of LSC-Exo with a portion of the spike protein — known as the receptor binding domain, or RBD — from the SARS-CoV-2 virus. A paper describing the research is published in Nature Biomedical Engineering.
“Vaccines can work through various means,” Cheng says. “For example, mRNA vaccines deliver a script to your cell that instructs it to produce antibodies to the spike protein. This VLP vaccine, on the other hand, introduces a portion of the spike protein to the body, triggering the immune system to produce antibodies to the spike protein.”
In rodent models, the RBD-decorated LSC-Exo vaccine (RBD-Exo) elicited production of antibodies specific to the RBD, and protected the rodents, after two vaccine doses, from infection with live SARS-CoV-2. Additionally, the RBD-Exo vaccine remained stable at room temperature for three months.
The researchers note that while the work is promising, there are still challenges associated with large-scale production and purification of the exosomes. LSCs, the cell type used for generating RBD-Exo, are currently in a Phase I clinical trial by the same researchers for treating patients with degenerative lung diseases.
“An inhalable vaccine will confer both mucosal and systemic immunity, it’s more convenient to store and distribute, and could be self-administered on a large scale,” Cheng says. “So while there are still challenges associated with scaling up production, we believe that this is a promising vaccine worthy of further research and development.”
The work was supported by the National Institutes of Health and the American Heart Association. North Carolina State University has filed a provisional patent on the technologies reported in those publications and the patent right has been exclusively licensed to Xsome Biotech, an NC State startup company co-founded by Cheng.
Story Source:
Materials provided by North Carolina State University. Original written by Tracey Peake. Note: Content may be edited for style and length.

Read more →

Most British COVID-19 mourners suffer PTSD symptoms, survey finds

More than eight out of 10 British people who are seeking support for having lost a loved one to COVID-19 reported alarming Post Traumatic Stress Disorder symptoms, new Curtin University-led research has found.
The study, based on data from people seeking help and guidance from the United Kingdom’s National Bereavement Partnership in collaboration with researchers from the Portland Institute for Loss and Transition and Christopher Newport University in the United States of America, also found almost two-thirds of British COVID-19 mourners experienced moderate or severe symptoms of anxiety and depression.
Lead author Professor Lauren Breen, from the Curtin School of Population Health, said the results were alarming given more than six million people had died from COVID-19 across the globe.
“These survey results indicate a concerning ‘shadow pandemic’ in the wake of a COVID-19 death with the vast majority of British mourners reporting alarming rates of psychological distress including constantly feeling on guard or easily startled,” Professor Breen said.
“The mourners who were seeking support from the National Bereavement Partnership also reported concerning symptoms of anxiety and depression, dysfunctional grief including wanting to die in order to be with their loved one, and functional impairment that was affecting their home and family responsibilities.”
According to the UK’s dedicated PTSD charity, PTSD UK, about 20 per cent of all PTSD cases worldwide are linked to the unexpected death of a loved one.

Read more →

Discovery could inspire new way to detect brain abnormalities

Scientists have taken a promising step towards a new generation of accurate, affordable and portable devices to detect concussion, epilepsy and dementia.
The international research team developed a laser-based diamond sensor that can measure magnetic fields up to 10 times more precisely than standard techniques. Their results are published in Science Advances.
Their innovation could help improve on existing magnetic-field sensing techniques for mapping brain activity to identify disorders. With sufficient funding and collaboration with industry, the team say they could develop a proof-of-concept device using their new sensor within five years.
Concussion in sport has been in the spotlight recently with prominent athletes sharing their stories about the significant ramifications of head injuries sustained during their careers. Meanwhile, about 250,000 Australians live with epilepsy, while nearly 500,000 Australians have some form of dementia.
The research is also relevant to a range of sectors beyond healthcare including mining, where it could lead to improved mineral exploration applications.
The study was led by Fraunhofer Institute for Applied Solid State Physics (IAF) in Germany — one of the leading organisations for applied research in Europe — working with RMIT University experts in diamond sensing technology Professor Andrew Greentree, Professor Brant Gibson and Dr Marco Capelli.

Read more →

How immune response triggered by COVID-19 may damage the brain

A study from the National Institutes of Health describes the immune response triggered by COVID-19 infection that damages the brain’s blood vessels and may lead to short- and long-term neurological symptoms. In a study published in Brain, researchers from the National Institute of Neurological Disorders and Stroke (NINDS) examined brain changes in nine people who died suddenly after contracting the virus.
The scientists found evidence that antibodies — proteins produced by the immune system in response to viruses and other invaders — are involved in an attack on the cells lining the brain’s blood vessels, leading to inflammation and damage. Consistent with an earlier study from the group, SARS-CoV-2 was not detected in the patients’ brains, suggesting the virus was not infecting the brain directly.
Understanding how SARS-CoV-2 can trigger brain damage may help inform development of therapies for COVID-19 patients who have lingering neurological symptoms.
“Patients often develop neurological complications with COVID-19, but the underlying pathophysiological process is not well understood,” said Avindra Nath, M.D., clinical director at NINDS and the senior author of the study. “We had previously shown blood vessel damage and inflammation in patients’ brains at autopsy, but we didn’t understand the cause of the damage. I think in this paper we’ve gained important insight into the cascade of events.”
Dr. Nath and his team found that antibodies produced in response to COVID-19 may mistakenly target cells crucial to the blood-brain barrier. Tightly packed endothelial cells help form the blood-brain barrier, which keeps harmful substances from reaching the brain while allowing necessary substances to pass through. Damage to endothelial cells in blood vessels in the brain can lead to leakage of proteins from the blood. This causes bleeds and clots in some COVID-19 patients and can increase the risk of stroke.
For the first time, researchers observed deposits of immune complexes — molecules formed when antibodies bind antigens (foreign substances) — on the surface of endothelial cells in the brains of COVID-19 patients. Such immune complexes can damage tissue by triggering inflammation.

Read more →

COVID-19 virus spike protein flexibility improved by human cell's own modifications

When the coronavirus causing COVID-19 infects human cells, the cell’s protein-processing machinery makes modifications to the spike protein that render it more flexible and mobile, which could increase its ability to infect other cells and to evade antibodies, a new study from the University of Illinois Urbana-Champaign found.
The researchers created an atomic-level computational model of the spike protein and ran multiple simulations to examine the protein’s dynamics and how the cell’s modifications affected those dynamics. This is the first study to present such a detailed picture of the protein that plays a key role in COVID-19 infection and immunity, the researchers said.
Biochemistry professor Emad Tajkhorshid, postdoctoral researcher Karan Kapoor and graduate student Tianle Chen published their findings in the Proceedings of the National Academy of Sciences.
“The dynamics of a spike are very important — how much it moves and how flexible it is to search for and bind to receptors on the host cell,” said Tajkhorshid, who also is a member of the Beckman Institute for Advanced Science and Technology. “In order to have a realistic representation, you have to look at the protein at the atomic level. We hope that the results of our simulations can be used for developing new treatments. Instead of using one static structure of the protein to search for drug-binding pockets, we want to reproduce its movements and use all of the relevant shapes it adopts to provide a more complete platform for screening drug candidates instead of just one structure.”
The spike protein of SARS-CoV-2, the virus that causes COVID-19, is the protein that juts out from the surface of the virus and binds to receptors on the surface of human cells to infect them. It also is the target of antibodies in those who have been vaccinated or recovered from infection.
Many studies have looked at the spike protein and its amino acid sequence, but knowledge of its structure has largely relied on static images, Tajkhorshid said. The atomistic simulations give researchers a glimpse of dynamics that affect how the protein interacts with receptors on cells it seeks to infect and with antibodies that seek to bind to it.

Read more →

Dominant omicron subvariants better at evading vaccines, antibody treatments

The latest omicron subvariants — including the BA.4 and BA.5 forms causing new surges in infections in the United States — are even better at eluding vaccines and most antibody treatments than previous variants, finds a study by researchers at Columbia University Vagelos College of Physicians and Surgeons.
The study, led by David D. Ho, MD, director of the Aaron Diamond AIDS Research Center and the Clyde’56 and Helen Wu Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons, was published July 5 in Nature.
Subvariants BA.2.12.1, BA.4, and BA.5 are rapidly expanding worldwide, with BA.4/5 now making up more than 50% of new COVID cases in the United States. These subvariants are thought to be even more transmissible than prior omicron subvariants, owing to several new mutations in spike proteins.
“The virus is continuing to evolve, as expected, and it is not surprising that these new, more transmissible subvariants are becoming more dominant around the world,” says Ho. “Understanding how currently available vaccines and antibody treatments stand up to the new subvariants is critical to developing strategies to prevent severe disease, hospitalizations, and deaths — if not infection.”
In laboratory experiments, Ho and his team studied the ability of antibodies from individuals who received at least three doses of an mRNA vaccine, or got two shots and were then infected with omicron, to neutralize the new subvariants. (Ho’s team did not look at individuals who had not received a booster shot, because a previous study found that two doses provide little protection against infection by earlier omicron variants.)
The study revealed that while BA.2.12.1 is only modestly more resistant than BA.2 in individuals who were vaccinated and boosted, BA.4/5 was at least four times more resistant than its predecessor.
In addition, the scientists tested the ability of 19 monoclonal antibody treatments to neutralize the variants and found that only one of the available antibody treatments remained highly effective against both BA.2.12.1 and BA.4/5.
“Our study suggests that as these highly transmissible subvariants continue to expand around the globe, they will lead to more breakthrough infections in people who are vaccinated and boosted with currently available mRNA vaccines,” Ho says. Though the current study suggests that the new variants may cause more infections in vaccinated individuals, the vaccines continue to provide good protection against severe disease.
“Efforts in the United States to develop new vaccine boosters aimed at BA.4/5 may improve protection against infection and severe disease,” Ho says. “In the current environment, though, we may need to look toward developing new vaccines and treatments that can anticipate ongoing evolution of the SARS-CoV-2 virus.”
Story Source:
Materials provided by Columbia University Irving Medical Center. Note: Content may be edited for style and length.

Read more →

A rhythmic small intestinal microbiome prevents obesity and type 2 diabetes

An estimated 500 to 1,000 bacterial species reside in each person’s gut, perhaps numbering 100,000 trillion microorganisms. In a new paper, published July 5, 2022 in Cell Reports, researchers at University of California San Diego School of Medicine used mouse models to explore how diet and feeding patterns affect these intestinal microbes — and the health of the hosts, particularly with obesity and type 2 diabetes.
In both mice and men, the ileum is the final stretch of the small intestine, connecting to the cecum, the first part of the large intestine. In the ileum, nutrients are drawn out of liquefied food; in the cecum, which also marks the beginning of the colon, the process of extracting water begins.
Both processes are complex, dynamic and profoundly influenced by factors ranging from the types of foods consumed and when, to the microbial residents of the gut, whose presence and behaviors help dictate digestion, absorption of nutrients, vitamin synthesis and development of the immune system.
“It’s important to realize that the gut microbiome is constantly changing, not only based on what we’re eating, but also based on the time of day,” said senior study author Amir Zarrinpar, MD, PhD, assistant professor of medicine at UC San Diego School of Medicine and a gastroenterologist at UC San Diego Health.
“Most researchers are getting snapshots of this constantly shifting environment, which makes it hard to understand what is going on in the gut. With this study, we are trying to get multiple snapshots throughout the day, almost like a movie, to better understand how food and the microbiome interact to affect weight gain and diabetes.
“And what we’ve learned is that cyclical changes in the gut microbiome are quite important for health since they help with the circadian clock, and with that the regulation and control of glucose, cholesterol and fatty acids — and overall metabolic health.”
In their latest work, Zarrinpar and colleagues further elucidate the impact and interplay of these factors, particularly in terms of the ileum and its unique functions related to digestion and absorption. Specifically, they looked at how diet-induced obesity (DIO) and time-restricted feeding (TRF) alter ileal microbiome composition and transcriptome (the protein-coding part of an organism’s genome) in mouse models.
The researchers found that in mouse models, DIO and the absence of TRF (mice could eat as much as they wanted whenever they wanted) resulted in disruptions to gut microbiome rhythms and the signaling pathways that help modulate intestinal clocks. In other words, the mice became fat and unhealthy.
“It is interesting that restricting food access with TRF acts not only through restoration of patterns affected under the unhealthy state, but also through new pathways,” said first author Ana Carolina Dantas Machado, PhD, a postdoctoral scholar in Zarrinpar’s lab.
“These findings underscore the influence of diet and time restricted feeding patterns in maintaining a healthy gut microbiome, which in turn modulates circadian rhythms that govern metabolic health,” said Zarrinpar. “It’s a very complicated relationship between the microbiome and the host, with the former helping determine the latter’s gastrointestinal functioning and health.”
Their work, said the authors, can inform future studies, in particular investigations of how the gut works or how drugs act upon the gut function depending upon the state of the microbiome at a particular time or time of day.
Co-authors include: Steven D. Brown, Amulya Lingaraju, Vignesh Sivaganesh, Cameron Martino, Peng Zhao, Antonio F.M. Pinto, Max W. Chang, R. Alexander Richter Alan R. Saltiel, Rob Knight and Satchidananda Panda, all at UC San Diego; Amandine Chaix, University of Utah; and Alan Saghatelian, Salk Institute for Biological Studies.

Read more →

Daily avocados improve diet quality, help lower cholesterol levels, study finds

Eating one avocado a day for six months was found to have no effect on belly fat, liver fat or waist circumference in people with overweight or obesity, according to a new study. However, it did lead to a slight decrease in unhealthy cholesterol levels.
In the randomized trial, the team — including Penn State researchers — also found that participants who ate avocados had better quality diets during the study period.
While prior, smaller studies have found a link between eating avocados and lower body weight, BMI, and waist circumferences, this was the largest, most extensive study to date on the health effects of avocados, including the large number of participants and length of the study period.
“While the avocados did not affect belly fat or weight gain, the study still provides evidence that avocados can be a beneficial addition to a well-balanced diet,” said Penny Kris-Etherton, Evan Pugh University Professor of Nutritional Sciences at Penn State. “Incorporating an avocado per day in this study did not cause weight gain and also caused a slight decrease in LDL cholesterol, which are all important findings for better health.”
Kristina Petersen, assistant professor of nutritional sciences at Texas Tech University, said the study also found that eating avocados daily improved the overall quality of the participants’ diets by eight points on a 100-point scale.
“Adherence to the Dietary Guidelines for Americans is generally poor in the U.S., and our findings suggest that eating an avocado per day can substantially increase overall diet quality,” Petersen said. “This is important because we know a higher diet quality is associated with lower risk of several diseases including heart disease, type 2 diabetes and some cancers.”
The research — recently published in the Journal of the American Heart Association — was conducted in conjunction with Loma Linda University, Tufts University, and UCLA, with coordinating support from Wake Forest University.

Read more →